OCUL — OCULAR THERAPEUTIX, INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1393434 ·
Last close
$8.94
Market Cap
$1.96B
52W High
$9.98
52W Low
$7.38
ADV30
2,665,779
Next earnings
2026-08-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 10,785,000 | 9,456,000 | -93,340,000 | -88,612,000 | 732,529,000 | 666,699,000 | 150,955,000 |
| Dec 2025 | 13,250,000 | 11,656,000 | -69,760,000 | -64,654,000 | 808,057,000 | 737,060,000 | 153,747,000 |
| Sep 2025 | 14,544,000 | 12,770,000 | -68,698,000 | -69,418,000 | 410,882,000 | 344,772,000 | 152,653,000 |
| Jun 2025 | 13,459,000 | 11,515,000 | -67,641,000 | -67,814,000 | 451,333,000 | 391,134,000 | 145,417,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-204,883,000
Investing CF
$-11,880,000
Financing CF
$561,721,000
CapEx
$-12,010,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.44
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,157,023,000
Inventory
$3,564,000
Receivables
$30,650,000
ST Investments
—
EBIT TTM
$-254,105,000
Pretax Income TTM
$-265,939,000
Interest Exp TTM
$11,834,000
Analysts
11
Yahoo Snapshot (yfinance, live)
Total Revenue
$52,038,000
EBITDA
$-294,815,008
Free Cash Flow
$-148,761,504
Enterprise Value
$1,381,216,640
Total Cash
$666,699,008
Total Debt
$79,462,000
Shares Out
218,960,358
Trailing EPS
$-1.44
Book Value
$2.66
ROE
-68.6%
ROA
-32.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 51,951,000 | -270,017,000 | -265,939,000 | 808,057,000 | 153,747,000 | — | -204,883,000 |
| Dec 2024 | 63,723,000 | -171,781,000 | -193,506,000 | 457,935,000 | 142,591,000 | — | -134,677,000 |
| Dec 2023 | 58,443,000 | -82,382,000 | -80,736,000 | 252,060,000 | 160,929,000 | — | -70,234,000 |
| Dec 2022 | 51,494,000 | -78,654,000 | -71,038,000 | 149,289,000 | 113,910,000 | — | -59,603,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.52
Max Pain — expiry 2026-06-18
max pain strike: $9.00 · spot: $8.94 · call oi: 20,450 · put oi: 5,429
Expected Move to 2026-06-18:
±$2.05
(22.93%) —
implied range
$6.89 –
$10.99
· ATM straddle on $9.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| HRMY | Harmony Biosciences Holdings, Inc. | $1.96B | $33.83 | — |
| RTEZ | REST EZ Inc. | $1.93B | $70.00 | — |
| ZLAB | Zai Lab Ltd | $1.99B | $17.73 | — |
| MBX | MBX Biosciences, Inc. | $1.91B | $40.09 | — |
| AGIO | AGIOS PHARMACEUTICALS, INC. | $1.89B | $31.84 | — |
News headlines (Yahoo Finance, 1h cache)
Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?
2026-06-15 20:30 · Yahoo
3 of Wall Street’s Favorite Stocks That Concern Us
2026-06-10 09:21 · Yahoo
Assessing Ocular Therapeutix (OCUL) Valuation After Recent Share Price Volatility
2026-06-05 19:11 · Yahoo
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-05 11:00 · Yahoo
Ocular Therapeutix™ to Participate in Clinical Trials at the Summit 2026
2026-06-04 11:00 · Yahoo
Ocular Therapeutix™ to Host Investor Day on June 17, 2026
2026-06-02 11:00 · Yahoo
1 Russell 2000 Stock to Research Further and 2 Facing Headwinds
2026-05-28 16:14 · Yahoo
Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1
2026-05-26 22:26 · Yahoo
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors
2026-05-19 17:26 · Yahoo
3 Stocks Under $10 That Fall Short
2026-05-15 15:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.